The Commercial segment of Pacific Edge focuses on the sales, marketing, and distribution of the Cxbladder suite of tests. This includes Cxbladder Triage, Detect, Monitor, and Resolve. The segment is responsible for establishing market access, securing reimbursement, and driving adoption of Cxbladder among urologists and healthcare providers. Key activities involve building strong relationships with key opinion leaders, generating clinical evidence to support the use of Cxbladder, and expanding the test's availability through partnerships with laboratories and healthcare systems. The Commercial segment is crucial for generating revenue and achieving sustainable growth for Pacific Edge.

The Research & Development segment is dedicated to the discovery, development, and validation of novel diagnostic and prognostic tools for cancer. This includes ongoing research into new biomarkers, refinement of existing Cxbladder tests, and development of new products for other cancer types, such as colorectal, gastric, endometrial cancers, and melanoma. The R&D segment collaborates with academic institutions and clinical partners to generate clinical evidence and validate the performance of its tests. A key focus is on leveraging genomic and proteomic technologies to identify and validate biomarkers that can improve the accuracy and early detection of cancer. This segment is essential for maintaining Pacific Edge's competitive advantage and expanding its product pipeline.